title: Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
abstract: OBJECTIVE
  In pediatric solid organ transplantation, the Epstein-Barr virus (EBV)-related lymphoproliferative disorders (PTLD) still play a major role in post-transplant morbidity and mortality. The aim of the study was to determine the incidence of PTLD in pediatric patients with liver transplant who receive low-dose immunosuppression protocols.
  
  
  METHODS
  All pediatric patients (n = 269) received a dual immunosuppression therapy consisting of cyclosporine A (initial trough levels, 170-200 microg/L; trough levels for maintenance immunosuppression after 1 year, 80-100 microg/L) and prednisolone (starting dose, 60 mg/m2). Steroids were reduced to 30 mg/m2 after 1 week, followed by a weekly tapering to 5 mg/m2. Seventy-seven of 269 patients were switched to tacrolimus therapy. The authors evaluated the significance of EBV-DNA monitoring by quantitative polymerase chain reaction in identifying patients at risk for PTLD.
  
  
  RESULTS
  Patient survival was 90.3%; graft survival was 85.9%. Eight patients lost their grafts because of chronic rejection. The incidence of PTLD was low (0.7%), although a significant EBV viral load was found in 42.4% of the patients. One third of the patients with a viral load of 3,000 genomes/10(5) cells or greater had clinical signs of EBV infection.
  
  
  CONCLUSIONS
  The authors conclude that low-dose immunosuppressive protocols significantly reduce the incidence of PTLD. In patients treated with that regimen, the monitoring of EBV viral load seems not to be helpful. It can be assumed that low-dose immunosuppression does not suppress EBV-specific cytotoxic CD8+ T cells, thus allowing the host to control EBV infection without the risk of PTLD. Our low-dose immunosuppression protocol did not increase the risk of chronic rejection.
authors.affiliation: Departments of Pediatrics, University of Hamburg, Germany. ganschow@uke.uni-hamburg.de
authors.forename: Rainer
authors.initials: R
authors.lastname: Ganschow
authors.forename: Tania
authors.initials: T
authors.lastname: Schulz
authors.forename: Thomas
authors.initials: T
authors.lastname: Meyer
authors.forename: Dieter C
authors.initials: DC
authors.lastname: Broering
authors.forename: Martin
authors.initials: M
authors.lastname: Burdelski
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage; D004279:DNA, Viral / Q000032:analysis / Q000302:isolation & purification; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015994:Incidence; D007223:Infant; D016031:Liver Transplantation; D008232:Lymphoproliferative Disorders / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D016559:Tacrolimus / Q000008:administration & dosage; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D016559:Tacrolimus